Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
|
|
|
5.
|
|
|
|
6.
|
|
|
|
7.
|
|
|
|
8.
|
|
|
|
9.
|
|
|
|
10.
|
|
|
|
11.
|
|
|
|
12.
|
|
|
|
13.
|
|
|
|
14.
|
|
|
|
15.
|
|
|
|
16.
|
|
|
|
17.
|
|
|
|
18.
|
|
|
|
19.
|
|
|
|
20.
|
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. [electronic resource] by
- Reich, K
- Warren, R B
- Iversen, L
- Puig, L
- Pau-Charles, I
- Igarashi, A
- Ohtsuki, M
- Falqués, M
- Harmut, M
- Rozzo, S
- Lebwohl, M G
- Cantrell, W
- Blauvelt, A
- Thaçi, D
Producer: 20210514
In:
The British journal of dermatology vol. 182
Availability: No items available.
|